跳至主要内容
临床试验/NCT03317171
NCT03317171已完成不适用

Studio Monocentrico in Doppio Cieco Randomizzato Dell'Effetto di Una Miscela di Flavonoidi ed Acidi Grassi Naturali in Pazienti Affetti da Distrofia Muscolare

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico2 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2016年2月28日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
29
试验地点
2
主要终点
Safety of the administered supplements

研究概览

简要总结

The study aimed to assess the safety and, partially, the efficacy of dietary supplementation of a flavonoids-, DHA- and EPA-based natural supplement in non-ambulant DMD boys and in a cohort of LGMD and FSHD patients to compare its effect in MDs of different aetiology and to eventually highlight any differences in inflammatory involved pathways. To assess safety, patient's laboratory parameters were monitored and adverse events recorded, while efficacy was evaluated through performance scale questionnaire and strength measurement (6 minute walking test and Biodex System 4 Dynamometer parameter evaluation). This study was conceived as proof of principle for the safe use of flavonoids/omega3s-based compound as an adjuvant in the management of neuromuscular disorders; besides, its efficacy in alleviating symptoms linked to secondary effects of genetic mutation as inflammation, muscular pain and weakness was assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
9 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Treated group

Experimental

oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.

干预措施: Flavonoids, DHA, EPA (Dietary Supplement)

Placebo group

Placebo Comparator

oral administration of placebo compound, once a day for 24 weeks.

干预措施: placebo compound (Dietary Supplement)

结局指标

主要结局

Safety of the administered supplements

时间窗: month 0 and month +6

blood tests, to monitor any possible change before and after the study

次要结局

  • Efficacy outcome - functional changes after the treatment(month 0, month +2, month +4, month +6)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验